Asthma Case Studies
Applying Guidelines and Latest Evidence to the Management of Moderate‐to‐Severe Asthma in Children and Adults
Speakers: Stacey Denham, MSW, MPH, Public Health ManagerAnju Peters, MD, MS, Professor of MedicineTheresa Guilbert, MD, MS, Professor
Duration: 60 minutes
Presented on: July 20, 2023
Stacey Denham, MSW, MPH
Stacey Denham, MSW, MPH
Public Health ManagerStacey Denham, MSW, MPH, is a Public Health Manager at the Asthma and Allergy Foundation of America (AAFA), the nation’s oldest and leading asthma and allergy charity. She holds an MSW and MPH from Tulane University with a concentration in Maternal and Child Health. Stacey has worked in the asthma and allergy field for over 15 years with an emphasis in community health. She has worked both locally in her community of New Orleans and internationally with non-profit organizations. Stacy believes in the power, diversity, and resilience of each community and the leaders that reside in them to bring healthy behavior change to positive health outcomes. Currently, Stacey resides in New Orleans with her family, where they can be found bike riding, trying out new food spots, and going to festivals.
Anju Peters, MD, MS
Anju Peters, MD, MS
Professor of MedicineAnju Peters, MD, MS, is a Professor in the Department of Medicine at Northwestern. Moreover, she is the Director of Clinical Research in the Division of Allergy-Immunology and the Medical Director of the Northwestern Medicine Clinical Research Unit. Furthermore, Dr. Peters is the Director of the Center for Clinical Research at the Northwestern University Clinical and Translational Sciences Institute. Her research focuses on the field of chronic rhinosinusitis and its associated comorbidities including allergic rhinitis, asthma and immunodeficiencies. Dr. Peters has published extensively in these areas and is currently involved in translational research and clinical trials in asthma and chronic rhinosinusitis. Currently, she practices as an allergist in the Division of Allergy-Immunology.
Theresa Guilbert, MD, MS
Theresa Guilbert, MD, MS
ProfessorTheresa Guilbert, MD, MS, is a Professor at the University of Cincinnati and the Director of the Asthma Center at Cincinnati Children’s Hospital & Medical Center. Dr. Guilbert’s clinical research focuses on identifying the roles of risk factors, exposures, and environment interactions that lead to early childhood wheezing and severe asthma as well as treatment and intervention strategies to manage asthma. Her clinical research has utilized stakeholder input to develop, implement, and test technology-based interventions for children with asthma, and she has developed a telehealth clinic which serves several urban core school-based health centers. Dr. Guilbert is currently the site PI for several multi-center asthma pediatric trials.
CME InformationApplying Guidelines and Latest Evidence to the Management of Moderate‐to‐Severe Asthma in Children and AdultsJointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC in collaboration with the Asthma and Allergy Foundation of America (AAFA).
ACKNOWLEDGEMENTThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
DATE OF RELEASE/EXPIRATIONThursday, July 20, 2023, from 4:00-5:00pm ET
TARGET AUDIENCEThe educational design of this activity addresses the needs of pulmonologists, allergists/immunologists, NPs and PAs, and other clinicians involved in the management of patients with moderate‐to‐severe asthma.
STATEMENT OF NEED/PROGRAM OVERVIEWPatients with asthma and underlying comorbidities require personalized treatment to achieve asthma control. Children with asthma have an especially high burden of symptoms, and are at risk of impaired lung development if asthma control cannot be achieved. Many patients with asthma are candidates for biologic therapies, which can significantly improve the burden of disease.
Join a panel of pulmonology and allergy experts, who will discuss patient cases to illustrate disease and management aspect of asthma with comorbidities. Panelists will review the negative impact of uncontrolled moderate‐to‐severe asthma on airway remodeling and lung development in children. Panelists will also discuss conditions that occur frequently with asthma and their shared pathophysiology as a treatment target. Current evidence, including long‐term data and guideline recommendations for asthma treatment will be explored, along with strategies to develop personalized treatment plans for patients based on asthma phenotype, biomarkers, and comorbidities.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Summarize the negative effects of comorbidities on the disease burden of moderate‐to‐severe asthma and on clinicians’ ability to achieve disease control
- Explain the negative consequences of failure to achieve control of moderate‐to‐severe asthma on lung development in children
- Apply current evidence and guidelines to identify appropriate biologic therapies for severe asthma based on phenotype, biomarkers, and comorbidities
JOINT ACCREDITATION STATEMENTIn support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team
PHYSICIAN CONTINUING EDUCATIONPACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 60 minutes to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
FACULTY AND DISCLOSURE OF CONFLICTS OF INTERESTPACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Name of Faculty or Presenter Reported Financial Relationship Theresa Guilbert, MD, MS
Professor of Pediatrics
Dept of Pediatrics, University of Cincinnati
Director of the Asthma Center
Cincinnati Children’s Hospital Medical Center
Consultant, Advisor, Speaker: AstraZeneca, Genentech, OM Pharma, Polarean, Regeneron, Sanofi
Researcher: Amgen, AstraZeneca, GlaxoSmithKline, OM Pharma, Regeneron, Sanofi
Anju T. Peters, MD, MSCI
Professor of Medicine
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Consultant, Advisor, Speaker: AstraZeneca, GlaxoSmithKline, Merck, Optinose, Sanofi Regeneron
Researcher: Merck, Sanofi Regeneron
Stacey Denham, MSW, MPH
Public Health Manager
Asthma and Allergy Foundation of America (AAFA)
No relevant financial relationships to disclose
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMERParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support:For additional information about the accreditation of this activity, please visit https://partnersed.com.
Technical Support:For any technical issues or issues with your CME Certificate, please contact ImmunologyLive or ResInsightsLive at 877-394-1306 or at Support@ImmunologyLive.com or Support@ResInsightsLive.com.